Sachin Mehta, MD
Ophthalmology · Phoenix, AZNPI 1619181260
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.0%. Reporting peaked in 2023 at $5,671 and has fallen 75.4% since, to $1,395 in 2025. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $127.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$5K
- Novartis$4K
- Regeneron$3K
- Bausch & Lomb Americas Inc.$3K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
- Cardinal Health 108 LLC$2K
- plus $5K from 19 others
Across 8 payments — averaging $3192.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$26K
What the payments were for
- Consulting fees$8,63137%
- Speaking & faculty fees$2,98513%
- Travel & lodging$9444%
- Food & beverage$10,75646%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 26 | $4,894 |
| Novartis | 9 | $4,403 |
| Regeneron | 12 | $2,587 |
| Bausch & Lomb Americas Inc. | 22 | $2,573 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $2,521 |
| Cardinal Health 108 LLC | 1 | $1,575 |
| Regeneron Healthcare Solutions, Inc. | 34 | $1,146 |
| Genentech USA, Inc. | 23 | $812 |
| Notal Vision, Inc. | 2 | $585 |
| Astellas Pharma US Inc | 15 | $543 |
| Apellis Pharmaceuticals, Inc. | 7 | $369 |
| Alcon | 8 | $345 |
| Dutch Ophthalmic, USA | 2 | $233 |
| Eyevance Pharmaceuticals LLC | 1 | $171 |
| Glaukos Corporation | 1 | $132 |
| Ivantis, Inc | 1 | $109 |
| ANI Pharmaceuticals, Inc. | 4 | $78 |
| AbbVie(2 entities) | 4 | $60 |
| Harrow Eye, LLC | 2 | $54 |
| Biogen | 2 | $45 |
| AstraZeneca | 1 | $43 |
| Genentech, Inc. | 1 | $34 |
| Spark Therapeutics, Inc. | 1 | $19 |
| Carl Zeiss Meditec USA, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,360 in reported general payments places this provider in the 90th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 246 | $7,734 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $3,390 |
| Alphagan PBrimonidine Tartrate | 11 | $2,145 |
| Ketorolac Tromethamine | 48 | $1,811 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 75 | $1,111 |
| MoxifloxacinMoxifloxacin Hcl | 42 | $997 |
| Brimonidine Tartrate | 138 | $871 |
| Timolol Maleate | 39 | $551 |
| Latanoprost | 46 | $536 |
| Ofloxacin | 50 | $526 |
| Atropine Sulfate | 11 | $442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieAlphagan P | $60 | $2,14511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Phoenix
- Pravin DugelPhoenix$176K
- Nishi ShahPhoenix$92K
- Karim JamalPhoenix$72K
- Benjamin HellerPhoenix$41K
- Neal PalejwalaPhoenix$33K
- Joshua DuncanPhoenix$30K
- Daniel ChurginPhoenix$15K
- John CasonPhoenix$14K
- Sujit IttyPhoenix$14K
- Elahhe AfkhamnejadPhoenix$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.